Anixa Ebit Per Revenue from 2010 to 2024

ANIX Stock  USD 3.32  0.10  3.11%   
Anixa Biosciences Ebit Per Revenue yearly trend continues to be fairly stable with very little volatility. Ebit Per Revenue is likely to outpace its year average in 2024. During the period from 2010 to 2024, Anixa Biosciences Ebit Per Revenue regression line of annual values had significance of  0 and arithmetic mean of (22.91). View All Fundamentals
 
Ebit Per Revenue  
First Reported
2010-12-31
Previous Quarter
(60.30)
Current Value
(57.28)
Quarterly Volatility
21.29701905
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Anixa Biosciences financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Anixa Biosciences' main balance sheet or income statement drivers, such as Interest Expense of 216.9 K, Selling General Administrative of 4.2 M or Total Revenue of 229.4 K, as well as many indicators such as Price To Sales Ratio of 861, Dividend Yield of 0.0 or PTB Ratio of 4.39. Anixa financial statements analysis is a perfect complement when working with Anixa Biosciences Valuation or Volatility modules.
  
Check out the analysis of Anixa Biosciences Correlation against competitors.
For more information on how to buy Anixa Stock please use our How to Invest in Anixa Biosciences guide.

Latest Anixa Biosciences' Ebit Per Revenue Growth Pattern

Below is the plot of the Ebit Per Revenue of Anixa Biosciences over the last few years. It is Anixa Biosciences' Ebit Per Revenue historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Anixa Biosciences' overall financial position and show how it may be relating to other accounts over time.
Ebit Per Revenue10 Years Trend
Slightly volatile
   Ebit Per Revenue   
       Timeline  

Anixa Ebit Per Revenue Regression Statistics

Arithmetic Mean(22.91)
Coefficient Of Variation(92.94)
Mean Deviation17.29
Median(16.76)
Standard Deviation21.30
Sample Variance453.56
Range60.2944
R-Value(0.73)
Mean Square Error225.42
R-Squared0.54
Significance0
Slope(3.49)
Total Sum of Squares6,350

Anixa Ebit Per Revenue History

2024 -57.28
2023 -60.3
2022 -52.43
2021 -0.00562
2019 -25.63
2018 -45.89
2017 -12.84

About Anixa Biosciences Financial Statements

Anixa Biosciences investors use historical fundamental indicators, such as Anixa Biosciences' Ebit Per Revenue, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Anixa Biosciences. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Ebit Per Revenue(60.30)(57.28)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Anixa Stock Analysis

When running Anixa Biosciences' price analysis, check to measure Anixa Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Anixa Biosciences is operating at the current time. Most of Anixa Biosciences' value examination focuses on studying past and present price action to predict the probability of Anixa Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Anixa Biosciences' price. Additionally, you may evaluate how the addition of Anixa Biosciences to your portfolios can decrease your overall portfolio volatility.